CytomX Corp (CTMX): יחס חוב לטווח ארוך להון

CytomX Therapeutics (CTMX) is integrating sustainability principles into the creation of precision medicines while simultaneously developing scientific alliances with global industry leaders to engineer modified antibodies. Price action on GURU.Markets is currently at 0.01. The biotech's growth relies on external partnerships to fund clinical trials without pursuing its own mergers and acquisitions.

A comparative asset analysis allows investors to assess the risk of declining returns via the ratio of liabilities with maturities exceeding one year to equity. For CytomX Therapeutics (CTMX), a biotech sector player developing targeted therapies in collaboration with pharma behemoths, this calculation determines the extent to which innovative growth depends on debt financing, which clearly reflects the trend of the long-term debt-to-equity ratio.